|
4-(2-amino-1H-imidazol-5-yl)-N,N-dihexylbutanamide;hydrochloride |
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
Ballard TE, et al. 2008. Chemistry |
|
5-(2-amino-1H-imidazol-5-yl)-N-hexylpentanamide;hydrochloride |
Depiction based on curated SMILES
ClH
H
2
N
N
H
N
CH
3
O
HN
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
Ballard TE, et al. 2008. Chemistry |
|
N-(3-(2-Aminopyrimidin-5-yl)prop-2-yn-1-yl)octanamide |
Depiction based on curated SMILES
H
2
N
N
N
CH
3
NH
O
|
Pseudomonas Staphylococcus |
Biofilm Biofilm |
Preclinical (in vitro) Preclinical (in vitro) |
Lindsey EA, et al. 2012. Org Biomol Chem
|
|
Mupirocin |
Depiction based on curated SMILES
O
O
O
HO
H
3
C
H
H
3
C
OH
H
H
H
O
H
H
3
C
O
H
H
H
HO
OH
|
Staphylococcus |
α-hemolysin |
Preclinical (in vitro) |
Jin Y, et al. 2018. Front Microbiol |
|
N-[3-(2-aminopyrimidin-5-yl)propyl]decanamide |
Depiction based on curated SMILES
NH
N
H
2
N
N
CH
3
O
|
Staphylococcus |
Biofilm |
Preclinical (in vitro) |
Lindsey EA, et al. 2012. Org Biomol Chem |
|
(E)-2-hydroxy-5-(5-(3-((1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)amino)-3-oxoprop-1-en-1-yl)furan-2-yl)benzoic acid |
Depiction based on curated SMILES
_
O
N
CH
3
CH
3
O
HO
OH
O
H
3
C
O
N
H
CH
3
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Leone M, et al. 2010. Chem Biol Drug Des |
|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |